Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Messing EM.

Bladder Cancer. 2018 Jan 20;4(1):131-132. doi: 10.3233/BLC-189027. No abstract available.

2.

Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer.

Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF.

Oncotarget. 2017 Aug 8;8(53):91199-91208. doi: 10.18632/oncotarget.20043. eCollection 2017 Oct 31.

3.

Bladder Sparing Therapy for BCG Failures - I - Intravesical Immunotherapy.

Messing EM.

Bladder Cancer. 2017 Oct 27;3(4):313-314. doi: 10.3233/BLC-179023. No abstract available.

4.

Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.

Truong M, Wang B, Gordetsky JB, Nix JW, Frye TP, Messing EM, Thomas JV, Feng C, Rais-Bahrami S.

Cancer. 2018 Jan 15;124(2):278-285. doi: 10.1002/cncr.31051. Epub 2017 Oct 4.

PMID:
28976544
5.

The BCG Shortage.

Messing EM.

Bladder Cancer. 2017 Jul 27;3(3):227-228. doi: 10.3233/BLC-179018. No abstract available.

6.

The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatory.

Horovitz D, Meng Y, Joseph JV, Feng C, Wu G, Rashid H, Messing EM.

Can Urol Assoc J. 2017 Jul;11(7):E285-E290. doi: 10.5489/cuaj.4150. Epub 2017 Jul 11.

7.

Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy.

Scosyrev E, Messing EM, Sylvester R, Van Poppel H.

Eur Urol Focus. 2017 Apr 4. pii: S2405-4569(17)30063-9. doi: 10.1016/j.euf.2017.02.015. [Epub ahead of print]

PMID:
28753863
8.

Rate of Symptomatic Lymphocele Formation After Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy and Bilateral Pelvic Lymphadenectomy.

Horovitz D, Lu X, Feng C, Messing EM, Joseph JV.

J Endourol. 2017 Oct;31(10):1037-1043. doi: 10.1089/end.2017.0153. Epub 2017 Aug 30.

PMID:
28741376
9.

A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

J Urol. 2018 Jan;199(1):106-113. doi: 10.1016/j.juro.2017.07.037. Epub 2017 Jul 18. Erratum in: J Urol. 2017 Dec 8;:.

PMID:
28728994
10.

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.

PMID:
28728992
11.

Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy.

Truong M, Rais-Bahrami S, Nix JW, Messing EM, Miyamoto H, Gordetsky JB.

Hum Pathol. 2017 Aug;66:206-211. doi: 10.1016/j.humpath.2017.06.017. Epub 2017 Jul 11.

PMID:
28705708
12.

Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.

Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM.

BJU Int. 2017 Sep;120(3):387-393. doi: 10.1111/bju.13904. Epub 2017 Jun 23.

PMID:
28464520
13.

Editorial Comment.

Messing EM.

J Urol. 2017 Feb;197(2):313. doi: 10.1016/j.juro.2016.08.134. Epub 2016 Oct 27. No abstract available.

PMID:
28346984
14.

Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma.

Messing EM.

Eur Urol. 2017 Jul;72(1):153-154. doi: 10.1016/j.eururo.2017.02.035. Epub 2017 Mar 11. No abstract available.

PMID:
28292548
15.

Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment.

Meng Y, Bernie HL, Weng TH, Ling DA, Messing EM, Guancial E.

Rare Tumors. 2016 Dec 20;8(4):6651. doi: 10.4081/rt.2016.6651. eCollection 2016 Nov 17.

16.

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.

Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

J Urol. 2017 Aug;198(2):316-321. doi: 10.1016/j.juro.2017.01.077. Epub 2017 Feb 3.

PMID:
28163032
17.

A More Thorough Transurethral Resection.

Messing EM.

Bladder Cancer. 2017 Jan 27;3(1):75-77. doi: 10.3233/BLC-169014. No abstract available.

18.

Extraperitoneal vs. transperitoneal robot-assisted radical prostatectomy in patients with a history of prior inguinal hernia repair with mesh.

Horovitz D, Feng C, Messing EM, Joseph JV.

J Robot Surg. 2017 Dec;11(4):447-454. doi: 10.1007/s11701-017-0678-0. Epub 2017 Jan 24.

PMID:
28120135
19.

Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery.

Horovitz D, Feng C, Messing EM, Joseph JV.

J Endourol. 2017 Apr;31(4):366-373. doi: 10.1089/end.2016.0706. Epub 2017 Mar 1.

PMID:
28073298
20.

Checkpoint Inhibitors for Advanced Bladder Cancer.

Messing EM.

Bladder Cancer. 2016 Oct 27;2(4):473-474. doi: 10.3233/BLC-169011. No abstract available.

21.

Surgical readmissions: results of integrating pre-, peri- and postsurgical care.

Noyes K, Baack-Kukreja J, Messing EM, Schoeniger L, Galka E, Pan W, Xueya C, Fleming FJ, Monson JR, Mohile SG, Francone T.

Nurs Open. 2016 May 10;3(3):168-178. eCollection 2016 Jul.

22.

Editorial Comment.

Messing EM.

Urology. 2016 Dec;98:63. doi: 10.1016/j.urology.2016.07.041. Epub 2016 Sep 29. No abstract available.

PMID:
27692685
23.

Beyond Cisplatin - I.

Messing EM.

Bladder Cancer. 2016 Jul 27;2(3):365-367. No abstract available.

24.

Editorial Comment.

Messing EM.

Urology. 2016 Aug;94:101. doi: 10.1016/j.urology.2016.03.050. Epub 2016 May 20. No abstract available.

PMID:
27215175
25.

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.

Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES.

PLoS One. 2016 May 17;11(5):e0155503. doi: 10.1371/journal.pone.0155503. eCollection 2016.

26.

Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study.

Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Nelson B, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing EM.

BJU Int. 2017 Jan;119(1):38-49. doi: 10.1111/bju.13521. Epub 2016 Jun 3.

27.

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S.

Oncotarget. 2016 May 10;7(19):27325-35. doi: 10.18632/oncotarget.8756.

28.

Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF.

Oncotarget. 2016 Apr 26;7(17):23335-45. doi: 10.18632/oncotarget.8024.

29.

Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES.

Anticancer Res. 2016 Feb;36(2):495-501.

PMID:
26851002
30.

Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists.

Baack Kukreja JE, Messing EM, Shah JB.

Urol Oncol. 2016 Mar;34(3):120.e17-21. doi: 10.1016/j.urolonc.2015.10.002. Epub 2015 Nov 14.

PMID:
26585947
31.

Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.

Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y.

BJU Int. 2016 May;117(5):783-6. doi: 10.1111/bju.13345. Epub 2015 Oct 29.

32.

Editorial Comment.

Kukreja JB, Messing EM.

Urology. 2015 Nov;86(5):972-3. doi: 10.1016/j.urology.2015.05.043. Epub 2015 Sep 26. No abstract available.

PMID:
26414727
33.

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K.

Diabetes Ther. 2015 Sep;6(3):357-75. doi: 10.1007/s13300-015-0128-9. Epub 2015 Sep 1.

34.

Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes.

Rink M, Crivelli JJ, Shariat SF, Chun FK, Messing EM, Soloway MS.

Eur Urol Focus. 2015 Aug;1(1):17-27. doi: 10.1016/j.euf.2014.11.001. Epub 2015 May 19. Review.

PMID:
28723350
35.

Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer.

Baack Kukreja JE, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G.

BJU Int. 2014 Dec;114(6):844-51. doi: 10.1111/bju.12543. Epub 2014 Jul 17.

36.

Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery.

Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM.

Urol Oncol. 2015 Sep;33(9):387.e7-16. doi: 10.1016/j.urolonc.2014.12.010. Epub 2015 Jan 29.

PMID:
25637953
37.

E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis.

Yasmin-Karim S, King MR, Messing EM, Lee YF.

Oncotarget. 2014 Dec 15;5(23):12097-110.

38.

Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.

Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S.

Oncotarget. 2014 Sep 15;5(17):7917-35.

39.

Editorial comment.

Messing EM.

J Urol. 2014 Oct;192(4):1077. doi: 10.1016/j.juro.2014.04.109. Epub 2014 Jul 8. No abstract available.

PMID:
25011050
40.

Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.

Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ.

Anticancer Res. 2014 May;34(5):2405-11.

PMID:
24778051
41.

A case series of transformation of teratoma to primitive neuroectodermal tumor: evolving management of a rare malignancy.

Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C.

Rare Tumors. 2014 Mar 18;6(1):5268. doi: 10.4081/rt.2014.5268. eCollection 2014 Jan 23.

42.

Impact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional study.

Fung C, Pandya C, Guancial E, Noyes K, Sahasrabudhe DM, Messing EM, Mohile SG.

J Urol. 2014 Sep;192(3):690-5. doi: 10.1016/j.juro.2014.03.098. Epub 2014 Apr 1.

PMID:
24704007
43.

Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression.

Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF.

J Urol. 2014 Aug;192(2):583-92. doi: 10.1016/j.juro.2014.02.035. Epub 2014 Feb 14.

PMID:
24530986
44.

Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men.

Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y.

Front Oncol. 2013 Dec 23;3:312. doi: 10.3389/fonc.2013.00312. eCollection 2013.

45.

Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3.

Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial E, Yeh S.

Carcinogenesis. 2014 Jun;35(6):1301-9. doi: 10.1093/carcin/bgt488. Epub 2013 Dec 28.

46.

Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results.

Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA.

J Clin Imaging Sci. 2013 Sep 30;3:41. doi: 10.4103/2156-7514.119139. eCollection 2013.

47.

N+, M0 prostate cancer: local therapy for systemic disease.

Messing EM.

Oncology (Williston Park). 2013 Jul;27(7):661-2, 668. No abstract available.

48.

Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.

Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H.

Eur Urol. 2014 Feb;65(2):372-7. doi: 10.1016/j.eururo.2013.06.044. Epub 2013 Jul 2.

PMID:
23850254
49.

Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries.

Donsky H, Coyle S, Scosyrev E, Messing EM.

Urol Oncol. 2014 Jan;32(1):40.e23-31. doi: 10.1016/j.urolonc.2013.04.010. Epub 2013 Jul 4.

PMID:
23831109
50.

Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification.

Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV.

Urology. 2013 Feb;81(2):324-31. doi: 10.1016/j.urology.2012.07.106.

PMID:
23374793

Supplemental Content

Loading ...
Support Center